Trial reportBMJ open2026
Effect of periprocedural antithrombotic medication on functional outcome and symptomatic intracranial hemorrhage in patients with carotid tandem lesions.
Trial report in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUp to 15% of patients with acute ischaemic stroke, eligible for endovascular treatment (EVT), have a carotid tandem lesion (TL) of atherosclerotic origin; defined as an extracranial carotid artery stenosis of ≥50% or occlusion with an intracranial large vessel occlusion. The optimal periprocedural antithrombotic (AT) management is unclear for this subgroup.
objectiveThis post-hoc analysis of the MR CLEAN-MED randomised multicentre clinical trial (ISRCTN76741621) evaluated the effect of various periprocedural AT regimens on outcomes in TL patients.
methodsTL patients randomised in the MR CLEAN-MED trial were included. Good functional outcome (GFO) was defined as modified Rankin Scale score of 0-2 at 90 days. Symptomatic intracranial haemorrhage (sICH) was classified according to the Heidelberg criteria. Outcomes were compared by AT regimen (aspirin, heparin or both aspirin and heparin) using logistic regression, adjusted for baseline variables.
resultsBetween 22 January 2018 and 27 January 2021, 628 patients were included, of which 100 had a TL. Among 76 patients receiving AT, 26 (34.2%) achieved GFO, versus 14/24 (60.9%) without AT (adjusted OR (aOR) 0.79, 95% CI 0.63 to 0.99). Rates of GFO were comparable across regimens; 30.4% with aspirin (aOR 0.82, 95% CI 0.61 to 1.11), 29.2% with heparin (aOR 0.75, 95% CI 0.57 to 0.99) and 41.4% with both (aOR 0.81, 95% CI 0.62 to 1.06).sICH occurred in 15.8% of AT treated patients versus 4.4% without AT (OR 4.31, 95% CI 0.53 to 35.02). By regimen, sICH rates were 17.4% with aspirin, 16.7% with heparin and 13.8% with both.
conclusionIn TL patients undergoing EVT, periprocedural AT was associated with worse functional outcome and there was a numerically higher rate of sICH; however, this association was not statistically significant and the estimate was imprecise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.